Evidence map›Paper›PMID 18053228›Full record

ArticleBMC clinical pharmacology2007

Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.

Ingeborg Hartz, Solveig Sakshaug, Kari Furu, Anders Engeland, Anne Elise Eggen, Inger Njølstad, Svetlana Skurtveit

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in BMC clinical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Use of Statins in Kidney Transplant Recipients in Norway.International journal of environmental research and public health · 2022
    Observational
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ingeborg HartzFaculty of Health Studies, Hedmark University College, Kirkeveieen 47, 2418 Elverum, Norway. ingeborg.hartz@hihm.no
Solveig Sakshaug
Kari Furu
Anders Engeland
Anne Elise Eggen
Inger Njølstad
Svetlana Skurtveit
Norwegian Institute of Public Health · NOUiT The Arctic University of Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA previous study has shown that variations in threshold and intensity (lipid goal attainment) of statins for primary prevention contribute to regional differences in overall consumption of statins in Norway. Our objective was to explore how differences in prevalences of use, dosing characteristics, choice of statin and continuity of therapy in individual patients adds new information to previous results.

methodsData were retrieved from The Norwegian Prescription Database. We included individuals from counties with high, average, and low statin consumption, who had at least one statin prescription dispensed during 2004 (N = 40 143).1-year prevalence, prescribed daily dose (PDD), statin of choice, and continuity of therapy assessed by mean number of tablets per day.

resultsThe high-consumption county had higher prevalence of statin use in all age groups. Atorvastatin and simvastatin were dispensed in 79-87% of all statin users, and the proportion was significantly higher in the high-consumption county. The estimated PDDs were higher than the DDDs, up to twice the DDD for atorvastatin. The high-consumption county had the highest PDD for simvastatin (25.9 mg) and atorvastatin (21.9 mg), and more users received tablets in the upper range of available strengths. Continuity of therapy was similar in the three counties.

conclusionAlthough differences in age-distribution seems to be an important source of variation in statin consumption, it cannot account for the total variation between counties in Norway. Variations in prevalences of use, and treatment intensity in terms of PDD and choice of statin also affect the total consumption. The results in this study seems to correspond to previous findings of more frequent statin use in primary prevention, and more statin users achieving lipid goal in the highest consuming county.

Indexed as

Patient SelectionAdministration, OralAdultAgedAged, 80 and overAge FactorsAtorvastatinDatabases, FactualDrug Administration ScheduleDrug PrescriptionsDrug UtilizationFemaleHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleAtorvastatinHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPravastatinPyrrolesSimvastatinTablets

Identifiers

PMID18053228
PMCPMC2234392
OpenAlexW2013048245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.